The Group's principal activity is developing biological products in the field of regenerative medicine. It is developing an adult stem cell platform for use in the global orthopedic industry, targeting a range of bone, cartilage and musculoskeletal conditions. The Group has the worldwide exclusive rights for orthopedic indications relating to a series of patents and technologies that have been developed over more than 10 years and which relate to the identification, extraction, and culture of adult Mesenchymal Precursor Cells (MPCs). The Group holds a substantial interest in Angioblast Systems Inc., an American company developing the same platform technology for the treatment of cardiovascular diseases, including repair and regeneration of blood vessels and heart muscle.
Alacra Alerts:
Receive alerts on the latest reports on Mesoblast Ltd
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
